scholarly journals Assessment of the effects of metformin and glibenclamide on the concentration of selected trace elements in type 2 diabetic patients

Pharmacia ◽  
2021 ◽  
Vol 68 (4) ◽  
pp. 845-849
Author(s):  
Jehan A. Mohammad ◽  
Ammar A. Y. Almulathanon ◽  
Fatimah Haitham Fathi
Keyword(s):  
Trace Elements ◽  
Serum Level ◽  
Treated Group ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Beneficial Effects ◽  
Serum Zn ◽  
Type 2 Diabetic

Metformin and glibenclamide may have beneficial effects on the levels of trace elements in diabetic patients. The aim of the current study was to assess the effects of metformin and glibenclamide on the concentrations of copper (Cu), zinc (Zn) and magnesium (Mg) in patients with type 2 diabetes mellitus. The metformin-treated patients showed significantly lower serum Cu levels compared with the untreated and glibenclamide groups. In addition, treatment with metformin was associated with a significant increase in serum concentrations of Zn compared to the newly diagnosed patients, whereas it did not show a noticeable alteration in the serum level of Mg. In contrast, the glibenclamide treated group revealed significantly higher Zn and Mg levels compared with the newly diagnosed group, while the serum level of Cu was not significantly modified. In conclusion, treatment with metformin led to a reduction in serum Cu and an increase in serum Zn concentrations, whereas glibenclamide treatment displayed enhancement in serum Zn and Mg levels.

scholarly journals Evaluating the Synergistic Activity of Metformin and Apple Cider Vinegar in Type 2 Diabetics

2020 ◽  
pp. 1-7
Author(s):  
Momina Abid ◽  
Farah Ahmed ◽  
Shehla Shaheen ◽  
Zahida Memon ◽  
M. Zaman Shaikh ◽  
...  
Keyword(s):  
Glycemic Control ◽  
The Body ◽  
Diabetic Patients ◽  
Synergistic Activity ◽  
Care Hospital ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Apple Cider ◽  
Type 2 Diabetic

Aims: The aim of this study was to observe the effect of Apple Cider Vinegar (ACV) in combination with Metformin on the Body Mass Index (BMI) and glycemic control of newly diagnosed type 2 diabetic patients. Study Design: Single arm pre post quasi experimental clinical trial. Place and Duration of Study: Department of Medicine of a tertiary care hospital and a Diabetes and Endocrinology clinic, based in Karachi, Pakistan from April to July 2019. Methodology: A total of 30 newly diagnosed type 2 diabetic patients were enrolled in the study (Males: 17; females: 13; age range: 27-55 years) after obtaining written informed consent. The parameters of Body weight, BMI, Fasting Blood Sugar (FBS) and Hemoglobin A1c (HbA1c) of each patient were assessed before and after 12 weeks of treatment with Metformin 750 mg plus 2 tablespoons of ACV per day. The baseline and post treatment values of the aforementioned were compared with each other. Results: In all the 30 patients assessed after 12 weeks of treatment, the weight was significantly reduced from 85.66±18.30 kg. to 82.96±18.43 kg with a consequently significant change in the BMI from 29.38±5.08 kg/m2 to 28.43±5.16 kg/m2. Moreover, the glycemic control, assessed as FBS and HbA1c also showed significant reduction in the FBS (127.76±9.17 to 121.23±9.54) and HbA1c (7.14±0.29 to 6.92±0.29) after 12 weeks of treatment in all 30 patients (p<0.01). Conclusion: Apple Cider Vinegar seems to be effective therapy in combination with metformin for newly diagnosed type 2 diabetic patients in improving glycemic control as well as augmenting weight reduction.

scholarly journals Resveratrol Promotes Foot Ulcer Size Reduction in Type 2 Diabetes Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Yuriy K. Bashmakov ◽  
Samir H. Assaad-Khalil ◽  
Myriam Abou Seif ◽  
Ruzan Udumyan ◽  
Magdy Megallaa ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Fibrinogen Level ◽  
Foot Ulcer ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Plasma Fibrinogen Level ◽  
Type 2 Diabetic Patients ◽  
Ulcer Size ◽  
Type 2 Diabetic

Objective. The effect of a proprietary formulation of trans-resveratrol (t-RSV) on manifestations of diabetic foot syndrome (DFS) was studied in type 2 diabetic patients with newly diagnosed diabetic foot ulcers. Method. Placebo-controlled, examiner-blinded, parallel-group randomized controlled pilot clinical trial (ACTRN Clinical Trial Registry number 12610000629033) involving 24 patients with DFS (15 males and 9 females, average age of 56.4±9.1 years) divided into the placebo and RSV-treatment groups was performed. 50 mg of t-RSV or placebo capsules was given to each patient twice a day over a 60-day time period. Results. Reduction in the parameters reflecting diabetic ulcer size was more profound in the RSV group as compared to placebo. RSV-treated patients also had a marginally improved performance in the foot pressure test. A statistically significant decline in the plasma fibrinogen level, but not CRP, was also found in the RSV-treated patients. Some improvement in the plasma lipid profile and fasting glucose levels were not related to RSV-treatment, since they have been seen on both the RSV and placebo groups, revealing the effectiveness of medical supervision and education in the newly diagnosed patients with DFS. Conclusion. t-RSV supplementation promotes reduction of the foot ulcer size and reduces plasma fibrinogen level in type 2 diabetic patients.

scholarly journals Healthy Behavior Change and Cardiovascular Outcomes in Newly Diagnosed Type 2 Diabetic Patients: A Cohort Analysis of the ADDITION-Cambridge Study

Diabetes Care ◽  
2014 ◽  
Vol 37 (6) ◽  
pp. 1712-1720 ◽  
Author(s):  
Gráinne H. Long ◽  
Andrew J.M. Cooper ◽  
Nicholas J. Wareham ◽  
Simon J. Griffin ◽  
Rebecca K. Simmons
Keyword(s):  
Behavior Change ◽  
Cohort Analysis ◽  
Cardiovascular Outcomes ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Healthy Behavior ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document